<DOC>
	<DOCNO>NCT02133911</DOCNO>
	<brief_summary>Recent data suggest area fibrosis hibernate myocardium develop patient non ischemic dilate cardiomyopathy . Ranolazine new drug , develop releave symptom angina patient stable coronary disease suitable surgical percutaneous revascularization . It show patient stable coronary disease Ranolazine improve myocardial perfusion show myocardial nuclear imaging . The aim trial evaluate effect ranolazine myocardial perfusion patient dilate cardiomyopathy .</brief_summary>
	<brief_title>A Pilot Trial Ranolazine Treat Patients With Dilated Cardiomyopathy</brief_title>
	<detailed_description>Recent data suggest area fibrosis hibernate myocardium develop patient non ischemic dilate cardiomyopathy . Ranolazine new drug , develop releave symptom angina patient stable coronary disease suitable surgical percutaneous revascularization . The main mechanism action Ranolazine inhibition late I ( Na ) thus decrease Ca++ load cardiomyocites . Consequently oxygen consumption also decrease . It also show patient stable coronary disease Ranolazine improve myocardial perfusion show myocardial nuclear imaging . The aim trial evaluate effect ranolazine myocardial perfusion patient dilate cardiomyopathy . Primary end-point : To determine wheather Ranolazine improve perfusion myocardium patient non-ischemic dilated cardiomyopathy . Secondary end-points : To determine wheather Ranolazine improve patient ' NYHA functional class , excercise capacity , LV systolic diastolic function weather ranolazine affect supraventricular ventricular arrhythmia occurance/frequency .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>establish diagnosis nonischemic dilate cardiomyopathy EF &lt; 35 % NYHA f.c . II IV Optimal medical management &gt; 6 month Age &lt; 75 year &gt; 18 year know hypersensitivity medication age &gt; 75 year &lt; 18 year EF &gt; 35 % renal insufficiency ( GF &lt; 30 ) liver dysfunction ( liver test &gt; 3x upper normal limit ) ) LQT syndrome drug affect CYP3A4 metabolism ( azoles , macrolides , calcineurin inhibitor etc . ) dementia active hemathological malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>